Tag Archives: ofatumumab

September, 2017

  • 6 September

    Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

    BOSTON–(BUSINESS WIRE)–Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta …

March, 2016

  • 11 March

    Genmab Submits its Supplemental BLA to the FDA for its CLL Combo

    Copenhagen, Denmark; March 10, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that a supplemental Biologics License Application (sBLA) has been submitted to the U.S. Food and Drug Administration (FDA) for the use of ofatumumab (Arzerra®) in combination with  fludarabine and cyclophosphamide (FC) for the treatment of patients with …